Compounds > 6-hydroxyadenosine
Page last updated: 2024-11-05

6-hydroxyadenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

6-Hydroxyadenosine (6-OH-Ado) is a naturally occurring nucleoside analog. It is a potent inhibitor of adenosine deaminase (ADA), an enzyme that catalyzes the deamination of adenosine to inosine. 6-OH-Ado is a potential therapeutic agent for the treatment of ADA deficiency, a genetic disorder that results in the accumulation of deoxyadenosine, which is toxic to cells. 6-OH-Ado has been shown to have antiviral activity against a number of viruses, including HIV-1, hepatitis C virus, and herpes simplex virus. It is also being investigated for its potential use in the treatment of cancer. 6-OH-Ado can be synthesized by a variety of methods, including enzymatic oxidation of adenosine using a flavin-containing monooxygenase. 6-OH-Ado is a promising lead compound for the development of new drugs for the treatment of a variety of diseases.'

Cross-References

ID SourceID
PubMed CID18881
CHEMBL ID236537
SCHEMBL ID3500846
MeSH IDM0054961

Synonyms (33)

Synonym
einecs 222-306-5
brn 0568198
ccris 2559
n(sup 6)-hydroxyadenosine
6-hydroxyamino-9-beta-d-ribofuranosylpurine
6-n-hydroxylaminopurine riboside
n(sup 6)-hydroxylaminopurine riboside
inosine oxime
6-hydroxyaminopurine ribonucleoside
n6-hydroxylaminopurine riboside
adenosine, n-hydroxy-
3414-62-8
n6-hydroxyadenosine
6-n-hydroxyadenosine
6-hydroxyaminopurine riboside
n-hydroxyadenosine
(2r,3r,4s,5r)-2-[6-(hydroxyamino)purin-9-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
CHEMBL236537
(2r,3r,4s,5r)-2-[6-(hydroxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
qr2s87k5xc ,
unii-qr2s87k5xc
SCHEMBL3500846
6-hydroxylamino-9-beta-d-ribofuranosylpurine
n6-hydroxyladenosine
inosine, 6-oxime
6-n-hydroxyamino-9-.beta.-d-ribofuranosylpurine
9-.beta.-d-ribofuranosyl-6-(hydroxylamino)purine
6-(hydroxylamino)-9-.beta.-d-ribofuranosylpurine
HY-118793
Q27287458
DTXSID701023373
CS-0068557
AKOS040749992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID595463Antiproliferative activity against human Caco2 cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
AID300107Selectivity index, ratio of CC50 for human KB cells to IC50 for Plasmodium falciparum K12007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID1653809Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 1 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID85703In vitro antiviral activity in secondary cultures of rabbit kidney cells infected with HSV type 1 strain HF1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID85569Concentration required to inhibit HSV type 1 strain HF induced cytopathogenic affects by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID521781Cytotoxicity against human HeLaS3 cells assessed cell viability at 0.05 after 24 hrs by Alamar blue assay2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues.
AID300108Selectivity index, ratio of CC50 for human KB cells to IC50 for Plasmodium falciparum VS12007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID300104Antimalarial activity against chloroquine, pyrimethamine and cycloguanil-resistant Plasmodium falciparum VS1 after 24 hrs2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID595459Antiproliferative activity against human HeLa cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
AID300106Selectivity index, ratio of CC50 for human KB cells to IC50 for Plasmodium falciparum 3D72007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID521783Antiviral activity against Poliovirus G64S infected in HeLaS3 cells at 2 mM after 6 hrs2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues.
AID1245165Cytotoxicity against mouse leukemia cells2015Bioorganic & medicinal chemistry, Sep-15, Volume: 23, Issue:18
Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials.
AID217834Concentration required to inhibit vaccinia virus induced cytopathogenic affects by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID217966In vitro for antiviral activity in secondary cultures of rabbit kidney cells infected with vaccinia virus1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Synthesis and antiviral activity of carbocyclic analogues of 2'-deoxyribofuranosides of 2-amino-6-substituted-purines and of 2-amino-6-substituted-8-azapurines.
AID96717Compound was tested for its antitumor activity to inhibit 50% of tumor cell growth in mouse leukemia L1210 cell lines.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity.
AID1653794Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 1 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID300103Antimalarial activity against chloroquine,pyrimethamine-resistant Plasmodium falciparum K1 after 24 hrs2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID228918Molar potency ratio was evaluated1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID521784Metabolic stability in human HeLaS3 cells assessed as JA28-triphosphate at 0.5 mM after 2 hrs by reverse-phase HPLC2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues.
AID25507HPLC capacity factor (k')1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID300105Cytotoxicity against human KB cells2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID155036Compound was tested for its antitumor activity to inhibit 50% of tumor cell growth in mouse leukemia P388 cell lines.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity.
AID521785Antiviral activity against Poliovirus infected in compound pre-treated HeLaS3 cells assessed as reduction in viral titer at 0.5 mM after 6 hrs relative to control2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues.
AID595460Antiproliferative activity against human K562 cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
AID521786Antiviral activity against Coxsackievirus infected in compound pre-treated HeLaS3 cells assessed as reduction in viral titer at 0.5 mM after 6 hrs relative to control2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues.
AID300102Antimalarial activity against drug-sensitive Plasmodium falciparum 3D7 after 24 hrs2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Anti-malarial activity of N6-modified purine analogues.
AID595462Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
AID1653804Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 1 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653799Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 1 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID595461Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's1 (12.50)18.2507
2000's2 (25.00)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.0310aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
hydroxyurea
[no description available]		2.2510one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		2.2510(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
pyrimethamine
Maloprim: contains above 2 cpds		2.0310aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
zonisamide
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.		2.25101,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
idoxuridine
[no description available]		1.9610organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		1.9610pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
methylthioinosine
Methylthioinosine: 6-(Methylthio)-9-beta-D-ribofuranosylpurine. An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.		1.9610purine ribonucleoside;
thiopurine
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.0310furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
amitriptyline n-oxide
[no description available]		2.2510organic tricyclic compound
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		2.3720beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
6-n-hydroxylaminopurine
N(6)-hydroxyadenine : A member of the class of 6-aminopurinnes that is adenine in which one of the exocyclic amino hydrogens is replaced by a hydroxy group.		2.03106-aminopurines;
hydroxylamines;
nucleobase analogue		mutagen;
teratogenic agent
3-deazaadenosine
3-deazaadenosine: RN given refers to parent cpd.		3.520
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.2510azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone: structure; from tobacco smoke		2.2510nitrosamine;
pyridines
zileuton
[no description available]		2.25101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
ziprasidone
ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.		2.25101,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		1.9610adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
nebularine
nebularine: structure. nebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage.		1.9610purine ribonucleoside;
purines D-ribonucleoside		fungal metabolite
2-aminoadenosine
[no description available]		1.9610purine nucleoside
nicotinamide n-oxide
[no description available]		2.2510pyridines
neplanocin a
neplanocin A: neplanocins are antitumor antibiotics & carbocyclic analogs of purine nucleosides from Ampullarilla regularis A11079; see also neplanocin B, neplanocin C, neplanocin D & neplanocin F; structure in first source; a potent inhibitor of S-adenosylhomocysteine hydrolase		3.2110
6-chloropurine riboside
[no description available]		2.3720
phenylisopropyladenosine
[no description available]		1.9610aromatic amine;
benzenes;
hydrocarbyladenosine;
purine nucleoside;
secondary amino compound		adenosine A1 receptor agonist;
neuroprotective agent
n-allyladenosine
[no description available]		1.9610purine nucleoside
6-methylpurine riboside
[no description available]		1.9610
n(6)-methoxyadenine
[no description available]		2.0310
2-amino-n(6)-hydroxyadenine
2-amino-N(6)-hydroxyadenine: mutagen & bacterial growth inhibitor; structure in first source. 2-amino-6-hydroxyaminopurine : A 2,6-diaminopurine that is the N(6)-hydroxy derivative of 2,6-diamino-3H-purine.		2.03102,6-diaminopurines;
hydroxylamines;
nucleobase analogue		mutagen;
teratogenic agent
n(6)-methoxyadenosine
[no description available]		2.7430
n-methyladenosine
N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.		1.9610methyladenosine
6-methoxypurine arabinoside
[no description available]		2.3720
n(4)-hydroxycytidine
N(4)-hydroxycytidine : A nucleoside analogue that is cytidine which carries a hydroxy group at the N(4)-positon. It has broad-spectrum antiviral activity against influenza, SARS-CoV , SARS-CoV-2 and MERS-CoV.		2.2510ketoxime;
nucleoside analogue		anticoronaviral agent;
antiviral agent;
drug metabolite;
human xenobiotic metabolite
n(6),n(6)-dimethyladenosine
N(6),N(6)-dimethyladenosine : A methyladenosine compound with two methyl groups attached to N(6) of the adenine nucleobase.		1.9610hydrocarbyladenosine
carbodine
carbodine: RN given refers to (R-(1alpha,2beta,3beta,4alpha))-isomer		1.9610
3'-c-methyladenosine
3'-C-methyladenosine: structure in first source		2.0610
n(6)-cyclopentyladenosine
[no description available]		1.9610
fosmidomycin monosodium salt
[no description available]		2.2510
n-(1-methyl-2-phenylethyl)adenosine, (s)-isomer
[no description available]		1.9610
1-aminoadenosine
1-aminoadenosine: structure		2.9340
benzamidoxime
benzamidoxime: structure given in first source. benzamidoxime : A member of the class of amidoximes obtained by formal condensation of the carbonyl group of benzamide with hydroxylamine.		2.2510amidoximebacterial metabolite;
genotoxin;
mammalian metabolite
guanoxabenz
[no description available]		2.2510
n(6)-cyclohexyladenosine
N(6)-cyclohexyladenosine: structure given in first source; receptors, purinergic P1 agonist		1.9610
upamostat
[no description available]		2.2510
ageladine a
Ageladine A: an antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai; structure in first source. ageladine A : An imidazopyridine that is 1H-imidazo[4,5-c]pyridin-2-amine substituted by a 4,5-dibromo-1H-pyrrol-2-yl group at position 4. It is an alkaloid isolated from a marine sponge Agelas nakamurai and acts as an inhibitor of the matrix metalloproteinases, the key enzymes involved in tumour growth, migration, angiogenesis, invasion and metastasis.		3.2110alkaloid;
aromatic amine;
imidazopyridine;
organobromine compound;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor;
metabolite
carbocyclic inosine
carbocyclic inosine: anti-Leishmanial agent; structure given in first source		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		01.9710
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9710